Deerfield Management and Biosymetrics Partner to Discover and Develop Novel Therapeutics

Collaboration to advance cardiology and neurology targets using phenomics and genomic data to improve human health

Deerfield Management, a healthcare investment firm, and BioSymetrics, a phenomics-driven drug discovery company,announced a five-year joint venture to accelerate the advancement of new therapeutics, with an initial focus on cardiovascular and neurological diseases. The collaboration will identify new drug discovery programs that combine BioSymetrics’ AI-powered target discovery and validation platform with Deerfield’s drug discovery and commercial modeling capabilities.

“BioSymetrics’ platform creates proprietary and highly valuable insights into biology that can help identify novel therapeutics,” said James Flynn, Managing Partner, Deerfield Management and Cure Founder. “Our collaboration focuses on complex conditions in cardiovascular and neurological disease where BioSymetrics’ data and analytical capabilities can be particularly important. We are excited about the breakthroughs possible through this partnership.”

Recommended AI News: Qeexo, and Bosch Enable Developers to Quickly Build and Deploy Machine-Learning Algorithms to Bosch AI-Enabled Sensors

BioSymetrics takes a phenomics-driven approach to advancing drug discovery. The company’s target discovery platform uses machine learning to connect clinical and experimental data – including patient data from millions of electronic medical records, genomics, and experimental data captured in zebrafish models using proprietary computer vision – to identify high-confidence targets for drug discovery. Targets discovered using BioSymetrics’ platform are grounded in human genetic evidence, giving them twice the likelihood of clinical success as demonstrated in the seminal paper by Matt Nelson, VP Genetics & Genomics at Deerfield Management. BioSymetrics is advancing programs in cardiometabolic, neurological, and rare diseases, including familial dilated cardiomyopathy, atherosclerosis, and epilepsy.

“Deerfield shares our philosophy of using human genetic evidence and rapid in vivo validation in target discovery,” said Anthony Iacovone, Co-founder and CEO. “For a prolific target discovery platform like ours, Deerfield’s strengths in drug discovery and healthcare expertise ensure that together we can aim to focus on the programs with the highest probability of success and drive forward the best science. We are enthusiastic to begin this effort and work together with Deerfield in translating complex clinical and experimental biology into actionable therapeutic development programs.”

Recommended AI News: Dell Technologies Storage Software Innovations Power New Levels of Automation, Security and Multi-Cloud Flexibility

Under the terms of the agreement, Deerfield and BioSymetrics will identify therapeutic targets using BioSymetrics’ platform and database. Deerfield will provide target product profiles and due diligence support, commercial modeling services, and drug development plans and infrastructure for projects that the parties decide to advance.

Recommended AI News: Basetwo Launches No-Code Artificial Intelligence Platform for Pharmaceutical Manufacturing, Raises $3.8 Million

[To share your insights with us, please write to sghosh@martechseries.com]

The post Deerfield Management and Biosymetrics Partner to Discover and Develop Novel Therapeutics appeared first on AiThority.

manufacturing
genomics
therapeutics
medical
healthcare
artificial intelligence
ai
machine learning
software
pharmaceutical
shares